Reactosome

Startup

Reactosome is advancing gene therapy with Synthetic Nucleus technology, grounded in two key innovations. The first is a precisely engineered, easily manufactured protein-based delivery compartment that allows targeted delivery of large therapeutic cargos without immune activation—overcoming key limitations of traditional carriers like LNPs and AAVs. The second is a synthetic expression system that enables sustained, finely adjustable RNA production within target cells, ensuring long-term therapeutic impact. Together, these components create a flexible platform applicable across a wide range of diseases. Reactosome is advancing a proprietary therapeutic pipeline and collaborating with pharmaceutical partners to address critical needs in gene therapy.